Fig. 7

Effect of Erk1/2, p38 MAPK, and PI3K/AKT signaling on vitality of IL-1β-stimulated OA-CH and of hsa-miR-126-3p mimic on phosphorylation of Erk1/2, PI3K/Akt, and p38 MAPK in IL-1β-treated OA-CH. a, b Viability and apoptosis of OA-CH after treatment with IL-1β, U0126 (MAPK/ERK inhibitor), LY294002 (PI3K/Akt inhibitor), and SB202190 (p38 MAPK inhibitor); n = 4. c–e Phosphorylation levels of Erk1/2, PI3K/Akt, and p38 MAPK in OA-CH were detected by western blotting; n = 4. All values represent mean ± standard deviation. Difference to control: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ^#difference between groups: ^#p < 0,05; ^##p < 0,01; ^###p < 0,001; ^####p < 0,0001; 1-way ANOVA with Newman-Keuls multiple comparison test